OUR EXPERTISE – YOUR SUCCESS
Helping you to realise your objectives
From start to successful completion
OUR PEOPLE
Klaus Manlik
Klaus Manlik
Managing Partner
More than 30 years experience in the pharmaceutical Industry
Ulrike Däxl
Ulrike Däxl
Managing Director Operations
Industry experience as a senior analyst for stock-listed pharmaceutical companies
Niek Stander
Niek Stander
Chief Commercial Officer
Experienced in pharmaceutical commercial, general management and financial leadership
Mathias Käsebier
Mathias Käsebier
Senior Director
Former executive of Boehringer Ingelheim – specialty in global OTC business and global nutritional supplements
OUR GLOBAL REACH
We are strong in Europe, Latin America and Emerging Markets and have an extensive global network
Proprietary Global Database
BANNERT MANLIK’s unique proprietary global database includes more than 22.000 companies and more than 50.000 individuals with public as well as non-public information:
- Rx companies
- OTC companies
- Generic companies
- Nutraceutical companies
- Phyto companies
- Biotech companies
- CMO’s
- CRO‘s
- Private Equity
- …and more
BANNERT MANLIK HEALTH CHECK PROCESS
Our Service Partner Network
Flexible outsourcing and payroll services
Recruitment of specialised roles
(GM, Sales/KAM, Medical, Market access etc.)
Interim managemnet provider
Banking relationships
Management of European Marketing
Authorisations and patent advice
Contract research and regulatory affairs
Contract manufacters
Market research
Why Bannert Manlik?
Working with a network
of consultants with significant industry experience
Proprietary global database
Access to companies and individuals
Solutions
designed for specific engagement
no generic templates
Multinational team
that is motivated,
result-oriented
and very efficient
Successfully
closed 600+ deals
Commitment:
from planning to execution
OUR LATEST SUCCESS STORIES (DEAL EXAMPLES)
Divestment of
a Colombian
Pharma Company
to a Spanish stock-listed
Pharma Company
Deal Size
25 mn USD
Divestment of a
global Gastro
brand
to a German
Pharma Company
Deal Size
250 mn USD
Divestment of
an European
antibiotic brand
to a Belgian
Pharma Company
Deal Size
40 mn USD
Divestment of a
global cardiovascular
brand
to a German
Pharma Company
Deal Size
200 mn USD
Divestment of
an European
OTC-brand
to a German
OTC Company
Deal Size
40 mn USD
Divestment of
a Mexican
Pharma Company
to a LatAm based
Pharma Company
Deal Size
60 mn USD
BANNERT MANLIK COMPANY HEALTH GENERATOR
OUR LATEST SUCCESS STORIES (DEAL EXAMPLES)
Final Strategy
Financial
Plan
Divenstment
Plan
Acquistion
Plan
Optimisation
Plan
Allocation of Responsibility for Strategy
About
Bannert Manlik Consultants
Since 1991, BANNERT MANLIK is one of the leading international strategic consulting fi rms for the pharmaceutical and healthcare industries.
We assist our clients throughout the entire M&A process, provide portfolio management strategies, as well as support in the realisation of international growth and other strategic goals.
CONTACT INFO
Our Office
Bannert Manlik Consultants GmbH
Maximilianstr. 4e
82319 Starnberg | Germany
Tel: + 49 . 8151. 973 65 0
info@bannert-manlik.com
Special newsletter
To support our clients in considering the effects of the COVID-19 crisis on their business, I will share over the next couple of weeks a number of newsletters on what companies should think about over the next few months to stabilize the company and to build for future success.
-
01 – COVID 19, Crisis and Financial Management
€0,00 In den Warenkorb
01 - COVID 19, Crisis and Financial Management
€0,00When preparing for crises, it is critical to fix the roof before it starts raining. Many of us have been ...- Categories: COVID-19 crisis.
- Tags: cash, cash flow projection, Financial Management, liquidity, working capital, working capital forecast.
-
02 – COVID 19, Crisis and Strategy
€0,00 In den Warenkorb
02 - COVID 19, Crisis and Strategy
€0,00In the past few weeks, we have overheard many people discussing how they have experienced an excellent performance in March ...- Categories: COVID-19 crisis.
- Tags: company strategy, external environment, PESTLE analysis, strategy, Strategy review.
-
03 – COVID 19, Crisis and Strategy Implementation
€0,00 In den Warenkorb
03 - COVID 19, Crisis and Strategy Implementation
€0,00While writing this plan, we have been intentional in considering the change management aspect. We believe that what most of ... -
04 – COVID 19, Crisis and Supply Chain Management
€0,00 In den Warenkorb04 - COVID 19, Crisis and Supply Chain Management
€0,00This is the last edition in our series of special COVID-19 newsletters on what companies could consider now and over ...
These newsletters are issued by Bannert-Manlik Consultants in association with Koru Financial Consulting.